Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?

Company Performance - Rigel Pharmaceuticals (RIGL) has seen a significant stock increase of 105.8% over the past month, reaching a new 52-week high of $43.72 [1] - Year-to-date, Rigel's stock has gained 146.7%, outperforming the Zacks Medical sector, which has seen a decline of 1.4%, and the Zacks Medical - Drugs industry, which has returned 10.6% [1] Earnings and Revenue - Rigel has consistently beaten earnings estimates, with the latest report on August 5, 2025, showing an EPS of $3.28 compared to a consensus estimate of $1.97, and a revenue beat of 28.99% [2] - For the current fiscal year, Rigel is projected to post earnings of $4.26 per share on revenues of $280.85 million, reflecting a 330.3% increase in EPS and a 56.65% increase in revenues [3] - The next fiscal year is expected to see a decline in earnings to $2.68 per share and revenues of $259.24 million, representing year-over-year changes of -37.18% and -7.69%, respectively [3] Valuation Metrics - Rigel has a Value Score of B, a Growth Score of A, and a Momentum Score of B, resulting in a VGM Score of A [6] - The stock trades at 9.7X current fiscal year EPS estimates, below the peer industry average of 16.1X, and at 38.5X trailing cash flow, compared to the peer group's average of 13X [6] Zacks Rank - Rigel holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, indicating potential for further gains [7] Industry Comparison - AMNEAL PHARMACEUTICALS, INC. (AMRX) is a notable peer with a Zacks Rank of 2 (Buy) and strong scores in Value (A), Growth (A), and Momentum (B) [8] - AMRX has also shown strong earnings performance, beating consensus estimates by 38.89%, and is expected to post earnings of $0.76 per share on revenues of $3.01 billion for the current fiscal year [9] - The Medical - Drugs industry is positioned in the top 35% of all industries, suggesting favorable conditions for both RIGL and AMRX [10]